Mutant KRAS and GNAS DNA concentrations in secretin-stimulated pancreatic fluid collected from the pancreatic duct and the duodenal lumen

Clinical and Translational Gastroenterology

Volumn 5, Issue 11, 2014, Pages

  Sadakari, Yoshihiko ^a   Kanda, Mitsuro ^a   Maitani, Kosuke ^a   Borges, Michael ^a   Canto, Marcia I ^a   Goggins, Michael ^a  

^a DEPARTMENT OF PATHOLOGY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DNA; K RAS PROTEIN; SECRETIN;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL (TOPIC); DNA CONTENT; DNA DETERMINATION; DUODENUM; DUODENUM FLUID; ENDOSCOPIC ECHOGRAPHY; ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY; FEMALE; GENE MUTATION; GNAS GENE; HIGH RESOLUTION MELTING ANALYSIS; HUMAN; MALE; MIDDLE AGED; MUTATIONAL ANALYSIS; ONCOGENE K RAS; PANCREAS CANCER; PANCREAS CYST; PANCREAS DUCT; PANCREAS JUICE; PRIORITY JOURNAL; PYROSEQUENCING;

EID: 84927913450     PISSN: None     EISSN: 2155384X     Source Type: Journal    
DOI: 10.1038/ctg.2014.14     Document Type: Article

References (29)

1. Rahib L, Smith BD, Aizenberg R et al. Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States. Cancer Res 2014; 74: 2913-2921.
2. Ferrone CR, Pieretti-Vanmarcke R, Bloom JP et al. Pancreatic ductal adenocarcinoma: long-term survival does not equal cure. Surgery 2012; 152: S43-S49.
3. Canto MI, Hruban RH, Fishman EK et al. Frequent detection of pancreatic lesions in asymptomatic high-risk individuals. Gastroenterology 2012; 142: 796-804 PMCID3321068.
4. Canto MI, Goggins M, Hruban RH et al. Screening for early pancreatic neoplasia in high-risk individuals: a prospective controlled study. Clin Gastroenterol Hepatol 2006; 4: 766-781.
5. Canto MI, Goggins M, Yeo CJ et al. Screening for pancreatic neoplasia in high-risk individuals: an EUS-based approach. Clin Gastroenterol Hepatol 2004; 2: 606-621.
6. Ludwig E, Olson SH, Bayuga S et al. Feasibility and yield of screening in relatives from familial pancreatic cancer families. Am J Gastroenterol 2011; 106: 946-954.
7. Verna EC, Hwang C, Stevens PD et al. Pancreatic cancer screening in a prospective cohort of high-risk patients: a comprehensive strategy of imaging and genetics. Clin Cancer Res 2010; 16: 5028-5037.
8. Poley JW, Kluijt I, Gouma DJ et al. The yield of first-time endoscopic ultrasonography in screening individuals at a high risk of developing pancreatic cancer. Am J Gastroenterol 2009; 104: 2175-2181.
9. Langer P, Kann PH, Fendrich V et al. Five years of prospective screening of high-risk individuals from families with familial pancreatic cancer. Gut 2009; 58: 1410-1418.
10. Brentnall TA, Bronner MP, Byrd DR et al. Early diagnosis and treatment of pancreatic dysplasia in patients with a family history of pancreatic cancer. Ann Intern Med 1999; 131: 247-255.
11. Al-SukhniW, Borgida A, Rothenmund H et al. Screening for pancreatic cancer in a high-risk cohort: an eight-year experience. J Gastrointest Surg 2012; 16: 771-783.
12. Canto MI, Harinck F, Hruban RH et al. International Cancer of Pancreas Screening (CAPS) Consortium International Cancer of the Pancreas Screening (CAPS) Consortium summit on the management of patients with increased risk for familial pancreatic cancer. Gut 2013; 62: 339-347.
13. Tanaka M, Fernandez-Del Castillo C, Adsay V et al. International consensus guidelines 2012 for the management of IPMN and MCN of the pancreas. Pancreatology 2012; 12: 183-197.
14. Tanaka M, Chari S, Adsay V et al. International consensus guidelines for management of intraductal papillary mucinous neoplasms and mucinous cystic neoplasms of the pancreas. Pancreatology 2006; 6: 17-32.
15. Brune K, Abe T, Canto M et al. Multifocal neoplastic precursor lesions associated with lobular atrophy of the pancreas in patients having a strong family history of pancreatic cancer. Am J Surg Pathol 2006; 30: 1067-1076.
16. Kanda M, Matthaei H, Wu J et al. Presence of somatic mutations in most early-stage pancreatic intraepithelial neoplasia. Gastroenterology 2012; 142: 730-733, e9.
17. Kanda M, Sadakari Y, Borges M et al. Mutant TP53 in duodenal samples of pancreatic juice from patients with pancreatic cancer or high-grade dysplasia. Clin Gastroenterol Hepatol 2013; 11: 719-730, e5.
18. Kanda M, Knight S, Topazian M et al. Mutant GNAS detected in duodenal collections of secretin-stimulated pancreatic juice indicates the presence or emergence of pancreatic cysts. Gut 2013; 62: 1024-1033.
19. Wu J, Matthaei H, Maitra A et al. Recurrent GNAS mutations define an unexpected pathway for pancreatic cyst development. Sci Transl Med 2011; 3: 92ra66.
20. Stevens T, Dumot JA, Zuccaro G Jr. et al. Evaluation of duct-cell and acinar-cell function and endosonographic abnormalities in patients with suspected chronic pancreatitis. Clin Gastroenterol Hepatol 2009; 7: 114-119.
21. Kanda M, Sadakari Y, Borges M et al. Mutant TP53 in duodenal samples of pancreatic juice from patients with pancreatic cancer or high-grade dysplasia. Clin Gastroenterol Hepatol 2013; 11: 719-730, e5.
22. Kimmey MB, Bronner MP, Byrd DR et al. Screening and surveillance for hereditary pancreatic cancer. Gastrointest Endosc 2002; 56: S82-S86.
23. Vasan N, Boyer J, Herbst RS. A RAS renaissance: emerging targeted therapies for KRASmutated non-small cell lung cancer. Clin Cancer Res 2014; 20: 3921-3930.
24. Nikiforova MN, Khalid A, Fasanella KE et al. Integration of KRAS testing in the diagnosis of pancreatic cystic lesions: a clinical experience of 618 pancreatic cysts. Mod Pathol 2013; 26: 1478-1487.
25. Jones S, Zhang X, Parsons DW et al. Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science 2008; 321: 1801-1806.
26. Matsubayashi H, Sato N, Brune K et al. Age- and disease-related methylation of multiple genes in nonneoplastic duodenum and in duodenal juice. Clin Cancer Res 2005; 11: 573-583.
27. Shi C, Klein AP, Goggins M et al. Increased prevalence of precursor lesions in familial pancreatic cancer patients. Clin Cancer Res 2009; 15: 7737-7743.
28. Andea A, Sarkar F, Adsay VN. Clinicopathological correlates of pancreatic intraepithelial neoplasia: a comparative analysis of 82 cases with and 152 cases without pancreatic ductal adenocarcinoma. Mod Pathol 2003; 16: 996-1006.
29. Cubilla AL, Fitzgerald PJ. Morphological lesions associated with human primary invasive nonendocrine pancreas cancer. Cancer Res 1976; 36: 2690-2698.